- $1.15bn
- $1.31bn
- $441.33m
Artivion Q1 revenue slightly beats, cuts 2026 outlook
U.S. STOCKS ON THE MOVE-UnitedHealth, Intel, Apple
U.S. STOCKS ON THE MOVE-Apple, Intel, Alignment Healthcare
Artivion rises as FDA clears minimally invasive aortic device
U.S. STOCKS ON THE MOVE -Health insurers, Arista, Savara
Artivion rises as FDA clears minimally invasive aortic device
Brief: Artivion Announces U.S. FDA Approval Of The Nexus® Aortic Arch System
Artivion slightly misses Q4 revenue estimates
Brief: Artivion Q4 Revenue USD 115.992 Million Vs. IBES Estimate USD 116.4 Million
Cardiovascular devices maker Artivion Q3 revenue beats estimates on growth in stent grafts
Brief: Artivion Enters Two Real Estate Purchase Agreements & Sale Contracts
U.S. RESEARCH ROUNDUP-Carmax, Mirion Technologies, Valmont Industries
Brief: Artivion - Enters Second Amendment To Credit Agreement - SEC Filing
Artivion Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Artivion Q2 Revenue USD 112.972 Million Vs. IBES Estimate USD 108 Million
Artivion Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Artivion Q1 Revenue USD 98.978 Million Vs. IBES Estimate USD 95 Million
Artivion Inc reports results for the quarter ended December 31 - Earnings Summary
Artivion Inc expected to post a loss of 6 cents a share - Earnings Preview